Ignite Creation Date:
2025-12-24 @ 9:25 PM
Ignite Modification Date:
2026-01-05 @ 5:50 PM
Study NCT ID:
NCT03035032
Status:
COMPLETED
Last Update Posted:
2024-11-26
First Post:
2017-01-25
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Study of ELIGARD® in Hormone-dependent Prostate Cancer Patients
Sponsor:
Astellas Pharma Singapore Pte. Ltd.
Organization:
Study Overview
Official Title:
A Phase IV Interventional Safety Study of ELIGARD® in Prostate Cancer Patients in Asia (ELIGANT)
Status:
COMPLETED
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The objective of this study was to evaluate the safety profile of ELIGARD® in ethnic Asian prostate cancer patients.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
True
Is an FDA AA801 Violation?: